๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› HER2 Negative Breast Cancer
Clinical trial register · China

HER2 Negative Breast Cancer Trials in China, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Shanghai 7 Beijing 3 Hangzhou 3 Guangzhou 2 Shijiazhuang 2
Narrow the registerReset
Recruitment status
Phase
Site location
Shanghai7 Beijing3 Hangzhou3 Guangzhou2 Shijiazhuang2
All 13 locations
Target enrolment
to

HER2 Negative Breast Cancer trials in China

15 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
Metronomic Oral Paclitaxel Monotherapy for Advanced HER2-Negative Breast Cancer: A Two-Stage Dose-Finding and Expansion Study
NCT07602907Advanced Breast Cancer, HER2-negative Breast Cancer
Zhejiang Cancer Hospital
Phase 2
73
Hangzhou
2026-08-04
Recruiting
Real-world Study of SKB264 Monotherapy or Combination Therapy in Recurrent or Metastatic HER2-negative Breast Cancer
NCT06993506HER2-negative Breast Cancer, Recurrence, Metastasis
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Observational
500
Hefei, Beijing, Fuzhou, Xiamen, Shijiazhuang, Zhengzhou, Shiyan, Wuhan
2026-05-28
Recruiting
CDK4/6 Inhibitors Combined With Endocrine Therapy for Neoadjuvant Treatment
NCT07366112Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
Peking University People's Hospital
Phase 2
158
Beijing
2026-04-20
Recruiting
Study on the Treatment of HER2-negative Breast Cancer Brain Metastases With Radiotherapy Combined With Anlotinib
NCT07396454HER2-Negative Breast Cancer
The First Affiliated Hospital with Nanjing Medical University
Phase 2
39
Nanjing
2026-02-10
Recruiting
ctDNA-Guided De-Escalation of Adjuvant Chemotherapy With Dalpiciclib in HR-Positive/HER2-Negative Breast Cancer
NCT06970912Hormone Receptor-Positive Breast Cancer, High-risk Breast Cancer, Early-Stage Breast Cancer, HER2-negative Breast Cancer
Peking University People's Hospital
Phase 2
393
Beijing
2025-08-01
Recruiting
Reverse HER2-negative Immune Resistant Breast Cancer
NCT06731140HER2 Negative Breast Cancer
Fudan University
Phase 2
10
Shanghai
2025-02-12
Recruiting
BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer
NCT06756932Hormone-receptor-positive Breast Cancer, HER2-negative Breast Cancer, Metastatic Breast Cancer
BeOne Medicines
Phase 1
120
Guangzhou, Zhengzhou, Shanghai, Tianjin, Hangzhou
2025-02-04
Recruiting
Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer
NCT06649331Advanced Breast Cancer, Metastatic Breast Cancer, Triple Negative Breast Cancer (TNBC), HER2-negative Breast Cancer
Fudan University
Phase 2
160
Shanghai
2024-10-21
Recruiting
Organoid-based Functional Precision Therapy for Advanced Breast Cancer
NCT06102824HER2-negative Breast Cancer, Advanced Breast Cancer
Guangdong Provincial People's Hospital
Phase 2
252
Guangzhou
2024-10-01
Recruiting
Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ยฑ Camrelizumab
NCT06516289BRCA-Mutated Breast Carcinoma, HER2-negative Breast Cancer
Fudan University
Phase 2
130
Shanghai
2024-09-30
Recruiting
Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis
NCT06230055HER2-negative Breast Cancer, Leptomeningeal Metastasis
Fudan University
Phase 4
37
Shanghai
2024-01-05
Recruiting
SNF Platform Study of HR+/ HER2-advanced Breast Cancer
NCT05594095Breast Neoplasm, Breast Cancer, Hormone Receptor Positive Tumor, HER2-negative Breast Cancer
Fudan University
Phase 2
620
Shanghai
2022-12-30
Recruiting
Clinical Study of Breast Conserving Surgery Combined With Intraoperative Radiotherapy for Early Breast Cancer
NCT06375798Breast Cancer, HER2-negative Breast Cancer
Hebei Medical University Fourth Hospital
Observational
620
Shijiazhuang
2020-11-19
Recruiting
Efficacy and Safety of Dose-dense Chemotherapy (ddEC-ddP) for Neoadjuvant Chemotherapy of HER2-negative Breast Cancer
NCT04576143HER2-negative Breast Cancer, Neoadjuvant Chemotherapy
Second Affiliated Hospital, Zhejiang University, School of Medicine
Phase 2/3
260
Hangzhou
2020-09-20
Rows per page Showing 1–15 of 15
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 26 September 2026. https://priyalifescience.com/clinical-trials-china/condition/her2-negative-breast-cancer

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 15 of those studies listing the condition HER2 Negative Breast Cancer.

How many HER2 Negative Breast Cancer trials are recruiting in China?

14 of the 15 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 1 have not yet opened recruitment, 0 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (HER2 Negative Breast Cancer), 15 studies
PhaseStudiesRecruitingShare
Phase 210966.7%
Observational2213.3%
Phase 1116.7%
Phase 2/3116.7%
Phase 4116.7%

Most active sponsors

Lead sponsors with the most studies (HER2 Negative Breast Cancer)
Lead sponsorStudiesRecruiting
Fudan University65
Peking University People's Hospital22
BeOne Medicines11
Cancer Institute and Hospital, Chinese Academy of Medical Sciences11
Guangdong Provincial People's Hospital11
Hebei Medical University Fourth Hospital11
Second Affiliated Hospital, Zhejiang University, School of Medicine11
The First Affiliated Hospital with Nanjing Medical University11
Zhejiang Cancer Hospital11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.